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INTRODUCTION
Familial hypokalemic periodic paralysis (HOPP) is an auto-
somal dominant disorder characterized by episodic attacks
of muscle weakness with concomitant hypokalemia (<3.5
mEq/L), which usually involves the four limbs. The age at
onset of paralytic crises is usually within the first or second
decade. The frequency of attacks is maximal between 15 and
35 yr of age and then decreases with age (1-3). The precipitat-
ing factors include carbohydrate- or sodium-rich meals, emo-
tional stress, and rest after exercise. The interval between cri-
sis can vary, and may be prolonged with preventive measures,
including avoidance of triggering factors, dietary changes, and
appropriate medications. 
Recent molecular genetic analysis has shown that HOPP is
caused by mutations in a calcium channel gene (CACNA1S) or
a sodium channel gene (SCN4A) (2-7). However, the majority
of familial HOPP patients have mutations in the CACNA1S
gene located on chromosome 1q31-32 (8, 9). The CACNA1S
gene encodes the  1-subunit of a skeletal muscle voltage-
gated L-type calcium channel known as the dihydropyridine
(DHP) receptor. The phenotypes of each mutation have some
differences in the gender penetrance, and the clinical charac-
teristics including the response to medications (4, 9-13).
We describe a patient with a mutation of arginine 1239-to-
glycine (R1239G) in calcium channel which is the rarest one
in the reported familial HOPP patients. In Korea, several cases
of familial HOPP in children and adults have been reported
(14, 15), but DNA diagnosis for familial HOPP is sparse (16).
CASE REPORT
A 13-yr old boy presented with near-daily attacks of mild
to severe paralysis for the past 8 yr. The symptoms mainly
appeared in the morning and he usually awakened with weak-
ness of the four limbs to the point of difficulty in sitting and
walking. After the paralytic episode in the morning, he was
free of symptoms in the afternoon, but eating high-sodium
or carbohydrate foods and rest after vigorous exercise made
him weak or completely paralyzed again at any time. In fami-
ly history, his mother (41 yr old), maternal-grandmother
(81 yr old), maternal aunt (55 yr old) and her two sons (the
patient’s cousins, 23 and 27 yr old) were also suffering from
similar attacks of weakness or paralysis throughout their lives
(Fig. 1). The severity and frequency of attacks of grandmoth-
er and mother has decreased with age. Two cousins of the pro-
band were diagnosed HOPP 8 yr ago at our hospital. They
were treated with acetazolamide and potassium supplements.
Because there is no effect of such treatment, they stopped
taking the drugs and they were lost further medical support.
On admission, the proband showed non-specific findings
in physical examination, radiologic and laboratory findings
including muscle enzymes. During paralytic episodes, the
patient showed low serum potassium levels (3.2 mEq/L vs.
4.4 mEq/L between attack) and hypokalemic ECG findings,
such as ST segment depression and U-wave. There was no
myotonia in EMG findings. DNA examination identified a
nucleotide 3705 C to G mutation in exon 30 of CACNA1S
gene (Table 1). This mutation predicts codon change from
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A Korean Family of Hypokalemic Periodic Paralysis with Mutation in 
a Voltage-gated Calcium Channel (R1239G)
Hypokalemic periodic paralysis (HOPP) is a rare disease characterized by reversible
attacks of muscle weakness accompanied by episodic hypokalemia. Recent molec-
ular work has revealed that the majority of familial HOPP is due to mutations in a
skeletal muscle voltage-dependent calcium-channel: the dihydropyridine receptor.
We report a 13-yr old boy with HOPP from a family in which 6 members are affect-
ed in three generations. Genetic examination identified a nucleotide 3705 C to G
mutation in exon 30 of the calcium channel gene, CACNA1S. This mutation pre-
dicts a codon change from arginine to glycine at the amino acid position #1239
(R1239G). Among the three known mutations of the CACNA1S gene, the R1239G
mutation was rarely reported. This boy and the other family members who did not
respond to acetazolamide, showed a marked improvement of the paralytic symp-
toms after spironolactone treatment.
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arginine to glycine at amino acid position #1239 of axon 30
in the calcium channel gene (Fig. 2). The patient was treat-
ed with spironolactone (25 mg b.i.d.), and he showed a dra-
matic improvement in his symptoms within 2 days. Other
affected members of the family, including two cousins of the
proband, have also started taking spironolactone. They could
also themselves awaken refresh and move at their will through-
out the day.
DISCUSSION
Periodic paralyses constitute a group of human hereditary
muscles disorders. Based on the variations of serum potassium
levels during attacks, they can classify as HOPP or hyper-
kalemic periodic paralysis. Both are inherited via autosomal
dominant mode with a high penetrance. HOPP is the most
frequent cause of periodic paralysis. The prevalence of HOPP
has been estimated at 1/100,000. Although most individu-
als diagnosed with HOPP in Western countries were famil-
ial types, sporadic types with or without underlying diseases,
such as thyrotoxicosis and renal tubular acidosis have been
reported in Korea (14-16).
Three mutations of CACNL1A3 gene are known in familial
HOPP (7-9). CACNA1S encodes the  1-subunit of a skele-
tal muscle voltage-gated calcium channel termed the dihy-
dropyridine (DHP) receptor.  This channel is composed of
five subunits called  1,  2,  ,  , and  . The  1-subunit
constitutes the ion-conducting pore, and contains the recep-
tor for dihydropyridine and other ligands (17, 18), whereas
the other subunits regulate the function of the  1-subunit of
the channel. The  1-subunit is composed of four transmem-
brane domains (I to IV), each of them containing six trans-
membrane helices (S1 to S6) (Fig. 2). The amino-acid sub-
stitutions in the three mutations are as follows: the replace-
ment of a positively-charged arginine in position 528 in seg-
ment S4 of domain II by a weakly-positive histidine (R528H)
and an arginine in position 1239 in the S4 segment of the
fourth domain by either an histidine or a glycine (R1239H
and R1239G) (7, 9). Molecular studies in Caucasian fami-
lies demonstrated that R528H and R1239H are predomi-
nant mutations (4, 10), whereas the R1239G mutation was
only found in a single family (9). The molecular diagnosis
for familial HOPP was possible using PCR amplication of
genomic DNA followed by restriction-enzyme digestion. By
this method, the proband identified that the rare R1239G
mutation inherited in his family (Fig. 2, Table 1).
Recently, mutations in the sodium channel gene (SCN4A)
in HOPP were reported. The structure of the sodium chan-
nel is similar to that of the calcium channel and is composed
of 4 domains each with 6 segments. These mutations were
found in the domain II of the S4 segment like R528H in the
mutations of the calcium channel (4, 6). 
There are several studies for clinical comparisons in families
with different mutations (4, 10-12). Elbaz et al. (10) reported
that the R528H and the R1239H mutations had the simi-
lar mean age of onset, the number of acute attacks, and the
precipitating factors. However incomplete penetrance was
observed only in female patients with R528 mutation. Our
patients appeared to present severe symptoms in males, and
an earlier beginning and higher frequency of paralysis symp-
toms than the previously reported cases. The response to med-
*Controls used in this test are the corresponding mutants.
Mutation Restriction enzyme Control used Patient results
R528H Msp A1 I, cuts normal heterozygote normal
R1239G Sau 96 I, cuts normal heterozygote heterozygote
R1239H Bsp LU III, cuts mutant heterozygote normal
Table 1. Results of DNA analysis in the proband
Fig. 1. Pedigree of the HOPP family. The dark symbols are affect-
ed individuals. The proband is indicated by an arrow. The age of
the family members is designated by the number.
81
55
27 23 25 18 18 17 13 8 20
58 51 47 41 38 38
78 70
Fig. 2. Schematic diagram of the DHP receptor  1-subunit com-
posed of four domains of an internal homology (DI to DIV) con-
nected by intracellular loops. The R1239G mutation substitutes a
positively-charged arginine located within segment DIVS4 by a
neutral glycine.
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ications also seems to depend upon the mutations underlying
periodic paralysis (4, 13). The acetazolamide, a carbonic anhy-
drase inhibitor, has been considered highly effective in most
HOPP patients (19-21). However, several patients with the
R672G SCNA4 mutation (4) and a patient with the R672S
SCNA4 mutation (13) showed an exacerbation of the symp-
toms after acetazolamide treatment. Although we did not
perform DNA analysis for two cousins of the proband, they
experienced an exacerbation of symptoms with acetazolamide
treatment 8 yr ago. However, it has not been determined yet
that the R1239G mutation is associated with acetazolamide-
resistance. Our patients showed a remarkable improvement
of symptoms with spironolactone treatment. Spironolactone
and its derivatives are alternatives to acetazolamide if it is not
effective after the empirical initial use (22-26). The action
of the aldosterone antagonists on HOPP is not known. The
beneficial effects on HOPP cannot be explained by antago-
nism to the action of aldosterone on the renal or enteric excre-
tion of sodium and potassium (22). Although recent studies
have demonstrated that mutations in the calcium- and sodi-
um channels cause HOPP, the mechanism of these channels
in the pathophysiology of HOPP has not clearly been defined.
Several complications during the clinical courses have been
reported. Vascular myopathy, unexpected acute paralysis or
cardiac arrhythmia with hypokalemia, and possibly malignant
hyperthermia associated with anesthesia have been reported
(27, 28). 
In conclusion, genetic diagnosis of familial HOPP is very
useful for making a confirmative diagnosis, providing genetic
counseling for the family members and as well as for provid-
ing the appropriate treatment.
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